Claims for Patent: 9,416,362

Summary for Patent: 9,416,362

Title:	Methods and compositions for reducing viral genome amounts in a target cell
Abstract:	Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target cell. Also provided are pharmaceutical compositions, kits and systems for use in practicing the subject methods. The subject invention finds use in a variety of applications, including the treatment of subjects suffering from a viral mediated disease condition, e.g., an HCV mediated disease condition.
Inventor(s):	Sarnow; Peter (Palo Alto, CA), Jopling; Catherine L. (Beeston, GB), Lancaster; Alissa M. (Portland, OR)
Assignee:	The Board of Trustees of The Leland Stanford Junior University (Palo Alto, CA)
Application Number:	14/280,156
Patent Claims:	1. A pharmaceutical composition comprising: a) an antisense oligonucleotide complementary to miR-122 such that said antisense oligonucleotide binds to miR-122 and inhibits its activity, wherein the antisense oligonucleotide comprises a nucleotide sequence of SEQ ID NO:15; and b) a pharmaceutically acceptable carrier; wherein said composition is prepared by a method of i) providing said antisense oligonucleotide as a powder, and ii) reconstituting said powder into a liquid form with said pharmaceutically acceptable carrier. 2. The pharmaceutical composition of claim 1, wherein said pharmaceutically acceptable carrier is sterile water. 3. The pharmaceutical composition of claim 1, wherein the antisense oligonucleotide complementary to miR-122 comprises a 2'-O-methyl modification. 4. The pharmaceutical composition of claim 1, wherein said composition comprises 0.1 to 90% by weight said antisense oligonucleotide. 5. The pharmaceutical composition of claim 1, wherein said composition comprises 1 to 30% by weight said antisense oligonucleotide. 6. The pharmaceutical composition of claim 1, wherein said composition is formulated for parenteral administration. 7. The pharmaceutical composition of claim 6, wherein said parenteral administration comprises intravenous administration.

Details for Patent 9,416,362

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2024-05-04